Top Headlines

US hits Ranbaxy with injunction to boost manufacturing quality

The US has filed a “groundbreaking” injunction against Ranbaxy to force the generic giant to make “fundamental changes” at its plants.

Related news

News in brief

UPDATE

People on the move: jobs in pharma

in-PharmaTechnololist presents its weekly round-up of the latest appointments within the pharmaceutical industry, including news from Prosonix, GENO, and BioCryst.

EU could make API suppliers verify starting material sources

Europe is considering forcing API manufacturers to verify the source of starting materials as part of GMP revisions.

Simplifying taxes would encourage Pharma manufacturing in France, says govt advisory board

Simplification of French tax laws would incentivise Pharmas to manufacture drugs in the country according to a government advisory body.

Manufacturing issues round-up

in-PharmaTechnologist presents a round-up of issues within the pharmaceutical manufacturing industry, including Novartis’ plans to restart Nebraska ops and problems for Roche at it’s South Carolina facility.

Global Industry News

Jubilant buys Lilly out of early-phase JV from Outsourcing-Pharma.com

Jubilant Life Sciences has bought US drugmaker Eli Lilly’s stake in the early-stage development focused JV the firms set up in 2008.

Contract manufacturing round-up from Outsourcing-Pharma.com

Outsourcing-Pharma presents a round-up of the latest headlines within the world of contract manufacturing. Catalent and Patheon have each launched oral dosage partnership news, whilst Frontage and AMPAC have received regulatory go-aheads.

Covance shocks analysts with two year IT investment plan from Outsourcing-Pharma.com

Covance is accelerating IT investment faster and for longer than expected, resulting in 2012 guidance that met analysts’ “worst-case fears”.

People on the move: outsourcing jobs from Outsourcing-Pharma.com

Outsourcing-Pharma presents its weekly round-up of the latest changes on the pharmaceutical career ladder, including news from Patheon, Wolfe Laboratories, and Premier Research.

On your radar